Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients

Author(s): Uzma Karamat, Samina Ejaz*

Journal Name: Current Cancer Drug Targets

Volume 21 , Issue 2 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The prevalence of breast cancer is increasing at an alarming rate and thus demands exploration of the most relevant diagnostic biomarkers. RAD50 is a cancer susceptibility gene that encodes a DNA damage repairing protein. Its role in breast cancer as clinico-pathological specific biomarker has yet to be explored.

Objective: This study was aimed to investigate the RAD50 expression and its promoter’s methylation level variations in breast invasive carcinoma patients having different clinico-pathological features. This study further explored the mutational spectrum of RAD50 and the correlation of its expression with the survival of patients and the effectiveness of drugs used for treatment.

Methods: Enrichment analysis of RAD50 was accomplished using the platform of GeneCards. The information regarding RAD50 expression, its promoter methylation and impact on survival of patient was retrieved from TCGA and CPTAC databases. However, the effect of RAD50 expression on tumor’s response to various drugs was deduced through the analysis of CCLE and genomic of GDSC dataset.

Results: The promoter hyper-methylation and elevated expression of RAD50 was documented in various subgroups of breast invasive carcinoma. The subjects having low/medium expression levels were observed to survive longer than patients exhibiting high expression of RAD50 except for post-menopausal subjects. The frequency of missense mutations was higher in RAD50 than truncating mutations. Most of the drugs were found to have a positive correlation with RAD50 expression.

Conclusion: The status of RAD50 promoter’s methylation inversely correlates with the expression level of RAD50. While RAD50 is overexpressed in breast cancer patients and thus makes tumor resistant against many anti-cancer drugs.

Keywords: RAD50, breast cancer, CCLE drug, survival analysis, mutatome map, MRN complex, expression.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 09 October, 2020
Page: [163 - 176]
Pages: 14
DOI: 10.2174/1568009620666201009125507
Price: $65

Article Metrics

PDF: 32